Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK18 | Q7Z418 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 1/20 | 0.36 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.36 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21749307 | 0.94 | MAPT (0.49) | KCNK18MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL25786524 | 0.90 | KCNK18 (0.45) | KCNK18MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20552265 | 0.84 | ABCG2 (0.45) | MAPTSMN1; SMN2ALDH1A1TAS2R14ATM | |
| SCHEMBL21764708 | 0.83 | ALDH1A1 (0.44) | KCNK18MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20552652 | 0.83 | ALDH1A1 (0.46) | KCNK18MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL21749242 | 0.82 | TP53 (0.44) | KCNK18MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20552892 | 0.81 | ALDH1A1 (0.44) | KCNK18MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20552262 | 0.80 | KDM4E (0.52) | MAPTSMN1; SMN2ALDH1A1GAARAB9A | |
| SCHEMBL20553068 | 0.79 | CYP11B1 (0.44) | KCNK18MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL20552415 | 0.79 | YAP1 (0.47) | LTA4HYAP1TEAD4TEAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | KCNK18 3394/4885MAPT 516/4885SMN1; SMN2 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.